Matrine modulates HSC70 levels and rescues ΔF508-CFTR

Journal of Cellular Physiology

Volumn 227, Issue 9, 2012, Pages 3317-3323

  Basile, Anna ^a,b   Pascale, Maria ^a,b   Franceschelli, Silvia ^a   Nieddu, Erika ^c   Mazzei, Marco T ^c   Fossa, Paola ^c   Turco, Maria Caterina ^a,b   Mazzei, Mauro ^c  

^a UNIVERSITY OF SALERNO   (Italy)

^b Biouniversa Srl   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALOID; CHAPERONE; CYCLIC AMP; HEAT SHOCK COGNATE PROTEIN 70; MATRINE; OXYMATRINE; PROTEIN BAG3; QUINOLIZIDINE DERIVATIVE; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG;

ARTICLE; CELL MEMBRANE; CELL SURFACE; CYSTIC FIBROSIS; CYTOSOL; DOWN REGULATION; ENDOPLASMIC RETICULUM; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LUNG ALVEOLUS CELL; MODULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LOCALIZATION;

ALKALOIDS; CELL LINE; CELL MEMBRANE; CELL SURVIVAL; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; ENDOPLASMIC RETICULUM; EPITHELIAL CELLS; GENE EXPRESSION REGULATION; HSC70 HEAT-SHOCK PROTEINS; HUMANS; MOLECULAR CHAPERONES; MUTATION; PROTEIN BINDING; QUINOLIZINES;

EID: 84862074188     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24028     Document Type: Article

References (55)

1. Alberti S, Böhse K, Arndt V, Schmitz A, Höhfeld J. 2004. The cochaperone HspBP1 inhibits the CHIP ubiquitin ligase and stimulates the maturation of the cystic fibrosis transmembrane conductance regulator. Mol Biol Cell 15: 4003-4010.
2. Amaral MD. 2004. CFTR and chaperones. J Mol Neurosci 23: 41-47.
3. Amaral MD. 2006. Therapy through chaperones: Sense or antisense? Cystic fibrosis as a model disease. J Inherit Metab Dis 29: 477-487.
4. Amaral MD, Kunzelmann K. 2007. Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis. Trends Pharmacol Sci 28: 334-3341.
5. Ammirante M, Rosati A, Arra C, Festa M, Basile A, Falco A, Pascale M, d'Avenia M, Marzullo L, Belisario MA, Barbieri A, Giudice A, Chiappetta G, Vuttariello E, Monaco M, Bonelli P, Salvatore G, Di Benedetto M, Deshmane S, Khalili K, Turco MC, Leone A. 2010. IKKγ protein is a target of BAG3 regulatory activity in human tumor growth. Proc Natl Acad Sci USA 107: 7497-7502.
6. Carlile GW, Robert R, Zhang D, Teske KA, Luo Y, Hanrahan JW, Thomas DY. 2007. Correctors of protein trafficking defects identified by a novel high-throughput screening assay. ChemBioChem 8: 1012-1020.
7. Choo-Kang LR, Zeitlin PL. 2001. Induction of Hsp70 promotes ΔF508 CFTR trafficking. Am J Physiol Lung Cell Mol Physiol 281: L58-L68.
8. Cohen-Cymberknoh M, Shoseyov D, Kerem E. 2011. Managing cystic fibrosis: Strategies that increase life expectancy and improve quality of life. Am J Respir Crit Care Med 183: 1463-1471.
9. Davis PB. 2006. Cystic fibrosis since 1938. Am J Respir Crit Care Med 173: 475-482.
10. Ding PL, Huang H, Zhou P, Chen DF. 2006. Quinolizidine alkaloids with Anti-HBV activity from Sophora tonkinensis. Planta Med 72: 854-856.
11. Doong H, Rizzo K, Fang S, Kulpa V, Weissman AM, Kohn EC. 2003. CAIR-1/BAG-3 abrogates heat shock protein-70 chaperone complex-mediated protein degradation. J Biol Chem 278: 28490-28500.
12. Egan ME, Glöckner-Pagel J, Ambrose CA, Cahill PA, Pappoe L, Balamuth N, Cho E, Canny S, Wagner CA, Geibel J, Caplan MJ. 2002. Calcium-pump inhibitors induce functional surface expression of Delta F508-CFTR protein in cystic fibrosis epithelial cells. Nat Med 8: 485-492.
13. Gao LM, Han YX, Wang YP, Li YH, Shan YQ, Li X, Peng ZG, Bi CW, Zhang T, Du NN, Jiang JD, Song DQ. 2011. Design and synthesis of Oxymatrine analogues overcoming drug resistence in hepatitis B virus, through targeting host heat stress cognate 70. J Med Chem 54: 869-876.
14. Grove DE, Rosser MFN, Ren HY, Naren AP, Cyr DM. 2009. Mechanisms for rescue of correctable folding defects in CFTRDelta F508. Mol Biol Cell 20: 4059-4069.
15. Hoelen H, Kleizen B, Schmidt A, Richardson J, Charitou P, Thomas PJ, Braakman I. 2010. The primary folding defect and rescue of ΔF508 CFTR emerge during translation of the mutant domain. PLoS One 5: e15458.
16. Hu H, Wang S, Zhang C, Wang L, Ding L, Zhang J, Wu Q. 2010. Synthesis and in vitro inhibitory activity of matrine derivatives towards pro-inflammatory cytokines. Bioorg Med Chem Lett 20: 7537-7539.
17. Jiang C, Fang SL, Xiao YF, O'Connor SP, Nadler SG, Lee DW, Jefferson DM, Kaplan JM, Smith AE, Cheng SH. 1998. Partial restoration of cAMP-stimulated CFTR chloride channel activity in DeltaF508cells by deoxyspergualin. Am J Physiol 275: C171-C178.
18. Kalid O, Mense M, Fischman S, Shitrit A, Bibler H, Ben-Zeev E, Schutz N, Pedemonte N, Thomas PJ, Bridges RJ, Wetmore DR, Marantz Y, Senderowitz H. 2010. Small molecule correctors of F508del-CFTR discovered by structure-based virtual screening. J Comput Aided Mol Des 24: 971-991.
19. Kim Chiaw P, Wellhauser L, Huan LJ, Ramjeesingh M, Bear CE. 2010. A chemical corrector modifies the channel function of F508del-CFTR. Mol Pharmacol 78: 411-418.
20. Li CQ, Zhu YT, Zhang FX, Fu LC, Li XH, Cheng Y, Li XY. 2005. Anti-HBV effect of liposome-encapsulated matrine in vitro and in vivo. World J Gastroenterol 11: 426-428.
21. Li X, Chu W, Liu J, Xue X, Lu Y, Shan H, Yang B. 2009. Antiarrhythmic properties of long-term treatment with Matrine in arrhythmic rat induced by coronary ligation. Biol Pharm Bull 32: 1521-1526.
22. Loo MA, Jensen TJ, Cui L, Hou Y, Chang XB, Riordan JR. 1998. Perturbation of Hsp90 interaction with nascent CFTR prevents its maturation and accelerates its degradation by the proteasome. EMBO J 7: 6879-6887.
23. Meacham GC, Lu Z, King S, Sorscher E, Tousson A, Cyr DM. 1999. The Hdj-2/Hsc70 chaperone pair facilitates early steps in CFTR biogenesis. EMBO J 18: 1492-1505.
24. Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63.
25. O' Sullivan BP, Freedman SD. 2009. Cystic fibrosis. Lancet 373: 1891-1904.
26. Okiyoneda T, Harada K, Takeya M, Yamahira K, Wada I, Shuto T, Suico MA, Hashimoto Y, Kai H. 2004. Delta F508 CFTR pool in the endoplasmic reticulum is increased by calnexin overexpression. Mol Biol Cell 15: 563-574.
27. Okiyoneda T, Barrière H, Bagdàny M, Rabeh WM, Du K, Hohfeld J, Young JC, Lukacs GL. 2010. Peripheral protein quality control removes unfolded CFTR from the plasma membrane. Science 329: 805-810.
28. Pedemonte N, Lukacs GL, Du K, Caci E, Zegarra-Moran O, Galietta LJ, Verkman AS. 2005. Small-molecule correctors of defective deltaF508-CFTR cellular processing identified by high-throughput screening. J Clin Investig 115: 2564-2571.
29. Pedemonte N, Boido D, Moran O, Giampieri M, Mazzei M, Ravazzolo R, Galietta LJV. 2007. Structure-activity relationship of 1, 4-dihydropyridines as potentiators of the CFTR chloride channel. Mol Pharmacol 72: 197-207.
30. Peng ZG, Fan B, Du NN, Wang YP, Gao LM, Li YH, Liu F, You XF, Han YX, Zhao ZY, Cen S, Li JR, Song DQ, Jiang JD. 2010. Small molecular compounds that inhibit hepatitis C virus replication through destabilizing heat shock cognate 70 messenger RNA. Hepatology 52: 845-853.
31. Ratjen FA. 2009. Cystic fibrosis: Pathogenesis and future treatment strategies. Respiratory Care 54: 595-605.
32. Riordan JR. 2008. CFTR function and prospects for therapy. Annu Rev Biochem 77: 701-726.
33. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL, Drumm ML, Ianuzzi MC, Collins FS, Tsui LC. 1989. Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA. Science 245: 1066-1073.
34. Rosati A, Ammirante M, Gentilella A, Basile A, Festa M, Pascale M, Marzullo L, Belisario MA, Tosco A, Franceschelli S, Moltedo O, Pagliuca G, Lerose R, Turco MC. 2007. Apoptosis inhibition in cancer cells: A novel molecular pathway that involves BAG3 protein. Int J Biochem Cell Biol 39: 1337-1342.
35. Rosati A, Graziano V, De Laurenzi V, Pascale M, Turco MC. 2011. BAG3: A multifaceted protein that regulates major cell pathways. Cell Death Dis 2: e141.
36. Rubenstein RC, Zeitlin PL. 2000. Sodium 4-phenylbutyrate downregulates Hsc70: Implications for intracellular trafficking of ΔF508-CFTR. Am J Physiol Cell Physiol 278: C259-C267.
37. Sampson HM, Robert R, Liao J, Matthes E, Carlile GW, Hanrahan JW, Thomas DY. 2011. Identification of a NBD1-binding pharmacological chaperone that corrects the trafficking defect of F508del-CFTR. Chem Biol 18: 231-242.
38. Scott-Ward TS, Amaral MD. 2009. Deletion of Phe508 in the first nucleotide-binding domain of the cystic fibrosis transmembrane conductance regulator increases its affinity for the heat shock cognate 70 chaperone. FEBS J 276: 7097-7109.
39. Sears EH, Gartman EJ, Casserly BP. 2011. Treatment options for cystic fibrosis: State of the art and future perspectives. Rev Recent Clin Trials 6: 94-107.
40. Simmonds NJ, D'Souza L, Roughton M, Alton EW, Davies JC, Hodson ME. 2011. Cystic fibrosis and survival to 40 years: A study of CFTR function. Eur Respir 37: 1076-1082.
41. Singh OV, Pollard HB, Zeitlin PL. 2008. Chemical rescue of deltaF508-CFTR mimics genetic repair in cystic fibrosis bronchial epithelial cells. Mol Cell Proteomics 7: 1099-1110.
42. Stankiewicz M, Nikolay R, Rybin V, Mayer MP. 2010. CHIP participates in protein triage decisions by preferentially ubiquitinating Hsp70-bound substrates. FEBS J 277: 3353-3367.
43. Van Goor F, Straley KS, Cao D, Gonzalez J, Hadida S, Hazlewood A, Joubran J, Knapp T, Makings LR, Miller M, Neuberger T, Olson E, Panchenko V, Rader J, Singh A, Stack JH, Tung R, Grootenhuis PD, Negulescu P. 2006. Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 290: L1117-L1130.
44. Wang XP, Yang RM. 2003. Movement disorders possibly induced by traditional Chinese herbs. Eur Neurol 50: 153-159.
45. Wang ML, Zhou QL, Wang BX. 2001. Studies on metabolism of Oxymatrine by human intestinal bacteria. Zhongguo Zhong Yao Za Zhi 26: 272-274.
46. Wang X, Venable J, LaPointe P, Hutt DM, Koulov AV, Coppinger J, Gurkan C, Kellner W, Matteson J, Plutner H, Riordan JR, Kelly JW, Yates JR III, Balch WE. 2006. Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell 127: 803-815.
47. Wang Y, Loo TW, Bartlett MC, Clarke DM. 2007. Correctors promote maturation of cystic fibrosis transmembrane conductance regulator (CFTR)-processing mutants by binding to the protein. J Biol Chem 16: 33247-33251.
48. Wang YP, Liu F, He HW, Han YX, Peng ZG, Li BW, You XF, Song DQ, Li ZR, Yu LY, Cen S, Hong B, Sun CH, Zhao LX, Kreiswirth B, Perlin D, Shao RG, Jiang JD. 2010a. Heat stress cognate 70 host protein as a potential drug target against drug resistence in hepatitis B virus. Antimicrob Agents Chemother 54: 2070-2077.
49. Wang XJ, Liang L, Chang JL, Yang MH. 2010b. Toxicity of matrine in Kunming mice. Nan Fang Yi Ke Da Xue Xue Bao 30: 2154-2155.
50. Yin LL, Zhu XZ. 2005. The involvement of central cholinergic system in (+)-matrine-induced antinociception in mice. Pharmacol Biochem Behav 80: 419-425.
51. Yoo CL, Yu GJ, Yang B, Robins LI, Verkman AS, Kurth MJ. 2008. 4′-Methyl-4, 5′-bithiazole-based correctors of defective ΔF508-CFTR cellular processing. Bioorg Med Chem Lett 18: 2610-2614.
52. Younger JM, Ren HY, Chen L, Fields A, Patterson C, Cyr DM. 2004. A foldable CFTR-ΔF508 biogenic intermediate accumulates upon inhibition of the Hsc70-CHIP E3 ubiquitin ligase. J Cell Biol 167: 1075-1085.
53. Yuan F, Chen J, Wu WJ, Chen SZ, Wang XD, Su Z, Huang M. 2010. Effects of Matrine and Oxymatrine on catalytic activity of cytochrome P450s in rats. Basic Clin Pharmacol Toxicol 107: 906-913.
54. Zhang Y, Wang S, Li Y, Xiao Z, Hu Z, Zhang J. 2008. Sophocarpine and matrine inhibit the production of TNF-〈 and IL-6 in murine macrophages and prevent cachexia-related symptoms induced by colon26 adenocarcinoma in mice. Int Immunopharmacol 8: 1767-1772.
55. Zheng H, Chen G, Shi L, Lou Z, Chen F, Hu J. 2009. Determination of oxymatrine and its metabolite matrine in rat blood and dermal microdialysates by high throughput liquid chromatography/tandem mass spectrometry. J Pharm Biomed Anal 49: 427-433.